Patents Represented by Attorney Mary K. VanAtten

Find this attorney in the Justia Lawyer Directory

  • Cyclic derivatives as modulators of chemokine receptor activity
    Patent number: 7163937
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: January 16, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Percy H. Carter, Robert J. Cherney, Douglas G. Batt, John V. Duncia, Daniel S. Gardner, Soo S. Ko, Anurag S. Srivastava, Michael G. Yang
  • Cyclic amine derivatives and their uses
    Patent number: 7125895
    Abstract: This invention relates to novel arylalkyl cyclic amine derivatives. This invention also relates to chemokine receptor antagonists that are be effective as therapeutic agents and/or preventive agents for diseases such as atherosclerosis, rheumatoid arthritis, transplant rejection, psoriasis, asthma, ulcerative colitis, glomerulonephritis, multiple sclerosis, pulmonary fibrosis, and myocarditis, in which tissue infiltration of blood monocytes and lymphocytes plays a major role in the initiation, progression or maintenance of the disease. Furthermore, chemokine receptor antagonists also inhibit the interaction of viruses, which attack blood monocytes and lymphocytes, through the use of a chemokine receptor. One such example is the HIV virus.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: October 24, 2006
    Assignee: Bristol-Myers Squibb Pharma Research Labs, Inc.
    Inventors: Christine M. Tarby, Wilna Moree
  • Cyclic protein tyrosine kinase inhibitors
    Patent number: 7125875
    Abstract: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: October 24, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jagabandhu Das, Ramesh Padmanabha, Ping Chen, Derek J. Norris, Arthur M. P. Doweyko, Joel C. Barrish, John Wityak, Louis J. Lombardo, Francis Y. F. Lee
  • Benzylcycloalkyl amines as modulators of chemokine receptor activity
    Patent number: 7126010
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: October 24, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Dean A Wacker, John V Duncia, Joseph B Santella, III., Daniel S Gardner
  • Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazepine as HIV reverse transcriptase inhibitors
    Patent number: 7015214
    Abstract: The present invention relates to 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: March 21, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Donna M Bilder
  • 2, 4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
    Patent number: 6809109
    Abstract: The present invention relates to 2,4-disubstituted pyridine-N-oxide compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: October 26, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: James D. Rodgers, Haisheng Wang
  • Bicyclic and tricyclic amines as modulators of chemokine receptor activity
    Patent number: 6784200
    Abstract: The present application describes modulators of CCR3 of formula (I): A—E—NR1—G  (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: August 31, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: John V Duncia, Joseph B Santella, III, Daniel S Gardner, Dean A Wacker
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6780857
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: August 24, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, George V. DeLucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker, Ui Tae Kim
  • Heterocyclic piperidines as modulators of chemokine receptor activity
    Patent number: 6759411
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: October 18, 2001
    Date of Patent: July 6, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, George V. Delucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker
  • 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
    Patent number: 6706735
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: March 16, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Paul S. Watson, Soo S. Ko, George V. DeLucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker
  • N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6627629
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: September 30, 2003
    Assignee: Bristol-Myers Squibb Pharma
    Inventors: Soo S. Ko, James R. Pruitt, Dean A. Wacker, Douglas G. Batt
  • Phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines
    Patent number: 6617310
    Abstract: This invention relates generally to phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as HIV protease inhibitors, pharmaceutical compositions comprising the same, and methods of using the same for treating viral infection.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: September 9, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Robert F. Kaltenbach, George L. Trainor
  • Efficient method for the conversion of nitriles to amidines
    Patent number: 6610858
    Abstract: The present invention relates to processes for the conversion of nitriles to amidines in the preparation of compounds which are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex. The compounds described herein are potent thrombolytics and useful for the inhibition of platelet aggregation in the treatment of thromboembolic disorders.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: August 26, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Philip Ma, Pasquale N. Confalone, Hui-Yin Li
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6605623
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: August 12, 2003
    Assignee: Bristol-Myers Squibb Pharma Co.
    Inventors: Soo S. Ko, George V. DeLucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker
  • Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
    Patent number: 6596729
    Abstract: The present invention relates to tricyclic 2-pyridone compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: July 22, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: James D. Rodgers, Haisheng Wang, Mona Patel, Argyrios Arvanitis, Anthony J. Cocuzza
  • Tricyclic compounds useful as HIV reverse transcriptase inhibitors
    Patent number: 6593337
    Abstract: The present invention relates to tricyclic compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: July 15, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Barry L. Johnson, Mona Patel, James D. Rodgers, Christine M. Tarby, Rajagopal Bakthavatchalam
  • Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
    Patent number: 6555686
    Abstract: This invention relates generally to the asymmetric synthesis of quinazolin-2-ones that are useful as inhibitors of HIV reverse transcriptase. The synthesis is accomplished through the chiral ligand mediated addition of cyclopropylacetylide.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: April 29, 2003
    Assignee: Bristol-Myers Squibb Pharma
    Inventors: Rodney L. Parsons, Roberta L. Dorow, Akin H. Davulcu, Joseph M. Fortunak, Gregory D. Harris, Goss S. Kauffman, William A. Nugent, Lilian A. Radesca
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6492400
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: December 10, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, George V. DeLucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker, Ui Tae Kim
  • 4,4-disubstituted-1, 4-dihydro-2H-3, 1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same
    Patent number: 6492515
    Abstract: The present invention relates to benzoxazinones of formula I: or stereoisomeric forms or mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, methods of using the same for treating viral infection or as an assay standard or reagent, and intermediates and processes for making the same.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: December 10, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Joseph Marian Fortunak, Mona Patel
  • 5, 5-disubstituted-1, 5-dihydro-4, 1-benzoxazepin-2 (3H)-ones useful as HIV reverse transcriptase inhibitors
    Patent number: 6489320
    Abstract: The present invention relates to benzoxazepinones of formula I: or stereoisomeric forms or mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: December 3, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Anthony J. Cocuzza, James D. Rodgers